GERON CORP Interest Payable, Current
GERON CORP (GERN) had Interest Payable, Current of $0 as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2026-08-05
- 2026-06-30: Interest Payable, Current $0.00.
- 2026-03-31: Interest Payable, Current $0.00.
- 2025-12-31: Interest Payable, Current $3.11M.
- 2025-09-30: Interest Payable, Current $0.00.
| Period end | Interest Payable, Current |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 |
| 2025-12-31 | $3.11M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-07 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 |
| 2024-12-31 | $2.19M 10-K · filed 2026-03-02 |
| 2024-09-30 | $853.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $867.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $896.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $768.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $594.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $584.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $585.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $561.00K 10-K · filed 2024-02-28 |
| 2022-09-30 | $479.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | $422.00K 10-Q · filed 2022-08-11 |
| 2022-03-31 | $393.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $336.00K 10-K · filed 2023-03-16 |
| 2020-12-31 | $194.00K 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |